This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The EpiCentRx Myc and CD47 downregulating molecule with a range of proposed mechanisms, RRx-001, is a Ph. III clinical candidate with…
molecule
2 years ago ●
2 mins read
The Chinook LDHA/GO dual inhibitor, compound 7, targets two clinically validated targets for hyperoxaluria, a rare genetic disorder that results in…
molecule
2 years ago ●
1 min read
the X-Chem covalent BTK inhibitor, compound 6, is an example of a covalent inhibitor discovered using DNA-encoded library chemistry, and is…
molecule
2 years ago ●
1 min read
The Revolution Medicines KRASG12C inhibitor, RM-018, “glues” KRASG12C to the highly abundant chaperone protein, cyclophilin A, in a tri-complex (KRAS- inhibitor-cyclophilin A) stabilized by protein-protein…
molecule
2 years ago ●
2 mins read
The Genentech TRPA1 ion-channel inhibitor, GDC-0334, is an oral candidate for asthma that demonstrated target engagement in a non-invasive skin- based…
molecule
2 years ago ●
1 min read
The Bayer soluble guanylate cyclase (sGC) activator, BAY 1101042 (runcaciguat), is a once-daily (50 mg), oral clinical candidate in Ph. II…
molecule
2 years ago ●
1 min read
Load More
